Pyrimido[1,2-a]-purin-10(3H)-one, M(1)G, is less prone to artifact than base oxidation

Pyrimido[1,2-a]-purin-10(3H)-one (M(1)G) is a secondary DNA damage product arising from primary reactive oxygen species (ROS) damage to membrane lipids or deoxyribose. The present study investigated conditions that might lead to artifactual formation or loss of M(1)G during DNA isolation. The addition of antioxidants, DNA isolation at low temperature or non-phenol extraction methods had no statistically significant effect on the number of M(1)G adducts measured in either control or positive control tissue samples. The number of M(1)G adducts in nuclear DNA isolated from brain, liver, kidney, pancreas, lung and heart of control male rats were 0.8, 1.1, 1.1, 1.1, 1.8 and 4.2 M(1)G/10(8) nt, respectively. In rat liver tissue, the mitochondrial DNA contained a 2-fold greater number of M(1)G adducts compared with nuclear DNA. Overall, the results from this study demonstrated that measuring M(1)G is a reliable way to assess oxidative DNA damage because the number of M(1)G adducts is significantly affected by the amount of ROS production, but not by DNA isolation procedures. In addition, this study confirmed that the background number of M(1)G adducts reported in genomic DNA could have been overestimated by one to three orders of magnitude in previous reports

Clinical Evaluation of Adenosine Triphosphate Disodium Hydrate (ATP-2Na) for Asthenopia

To investigate the effect and the safety of Adenosine triphosphate disodium hydrate (ATP-2Na) for asthenopia. 40 subjects [35 females and 5 males, 25~87 years old (average: 62.5 years old)] with asthenopia ingested 200~300 mg/day ATP-2Na for 3 months. Before and after 1 and 3 months ingestion, subjects completed a questionnaire to determine their asthenopia symptom and fatigue symptom by visual analog scale (VAS). The scores were compared between before and after ingestion. 31 subjects completed a questionnaire for 1 month. The scores of asthenopia symptom before ingestion, 1 and 3 months were 4.05 ± 3.22, 2.67 ± 2.19 and 2.41 ± 2.16, respectively. The scores of fatigue symptom were 4.76 ± 3.05, 3.08 ± 2.93 and 3.10 ± 3.19, respectively. Both scores were significantly decreased (p < 0.005) at 1 month compared before ingestion. Three subjects had side effects (diarrhea for two, nausea for one), and all subjects improved by oral discontinuation. These results suggest that ATP-2Na is relatively early effective in improving asthenopia and accompanying fatigue symptoms